Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25771601 | 0.83 | RAB9A (0.49) | RAB9ALMNAMAPTALDH1A1KDM4E | |
| SCHEMBL12653399 | 0.75 | RAB9A (0.43) | RAB9ALMNAMAPTALDH1A1KDM4E | |
| SCHEMBL1322979 | 0.75 | RAB9A (0.49) | RAB9ALMNAMAPTALDH1A1KDM4E | |
| SCHEMBL19463937 | 0.74 | RAB9A (0.63) | RAB9ALMNAMAPTALDH1A1KDM4E | |
| SCHEMBL3196831 | 0.71 | ALDH1A1 (0.56) | RAB9ALMNAMAPTALDH1A1KDM4E | |
| SCHEMBL16612335 | 0.70 | RAB9A (0.42) | RAB9ALMNAMAPTALDH1A1KDM4E | |
| SCHEMBL19463838 | 0.70 | RAB9A (0.57) | RAB9ALMNAMAPTALDH1A1KDM4E | |
| SCHEMBL20338306 | 0.69 | RAB9A (0.60) | RAB9ALMNAMAPTALDH1A1KDM4E | |
| SCHEMBL23609124 | 0.69 | RAB9A (0.56) | RAB9ALMNAMAPTALDH1A1KDM4E | |
| SCHEMBL6506166 | 0.68 | KDM4E (0.45) | RAB9ALMNAMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115989224-B | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20230286958-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-09-14 | — | — | US | disclosed |
| CN-115989224-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286958-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | RAB9A 1956/4885LMNA 2426/4885MAPT 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.